|Home | Stock Market Blogs | Financial Tools | Sign Up Free|
|Johnson & Johnson||
|Johnson & Johnson|
|JNJ||Last: $59.76 ($+0.02)||Volume: 9,601,162||Last Trade: 8/5/2010 4:22:44 PM|
Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year
|Johnson & Johnson Profile|
|Johnson & Johnson is engaged in the worldwide manufacture and sale of a range of products in the health care field, and operates via three segments: Consumer; Pharmaceutical and Medical Devices; and Diagnostics. Co.'s Consumer segment includes a range of products used in the baby and child care, skin care, oral and wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. Co.'s Pharmaceutical segment includes products used as therapeutics. Co.'s Medical Devices and Diagnostics segment includes a range of products used primarily in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics.|
|Johnson & Johnson News & Press Releases|
Micrus Endovascular Reports Fiscal First Quarter 2011 Financial Results
Micrus Endovascular Corporation ( MEND ) today reported financial results for the three months ended June 30, 2010. Micrus reported total revenues o... [more]
Former McKinsey & Company Chairman and Managing Director Ian Davis Appointed to Johnson & Johnson Bo
NEW BRUNSWICK, N.J. , July 19 /PRNewswire-FirstCall/ -- Ian E.L. Davis , former Chairman and Worldwide Managing Director of McKinsey & Company, today was appointed to the Board of Directors of Johnson & John... [more]
Micrus Endovascular Board Being Investigated by The Law Office of Joseph Klein Following Johnson & J
The Law Office of Joseph Klein is investigating the Board of Directors of Micrus Endovascular Corporation (“Micrus” or the “Company”) (NasdaqGM: MEND) for... [more]
Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Micrus Endovasc
NEW YORK, July 14, 2010 (GLOBE NEWSWIRE) -- Levi & Korsinsky is investigating the Board of Directors of Micrus Endovascular Corporation ("Micrus" or the... [more]
Robbins Umeda LLP Announces an Investigation of the Acquisition of Micrus Endovascular Corporation b
Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Direct... [more]
Keller Rohrback L.L.P. Announces Investigation of Lung and Liver Problems Potentially Associated wit
Attorney Advertising. Keller Rohrback L.L.P. ( www.krclassaction.com ) announces that it is investigating possible claims against Johnson & Johnson... [more]
Keller Rohrback Announces Class Action Cases to Proceed Against Johnson & Johnson and Wal-Mart for S
SEATTLE, Feb. 9, 2010 (GLOBE NEWSWIRE) -- Attorney Advertising. Keller Rohrback L.L.P. ( www.krclassaction.com ) announces that the Court has ruled that... [more]
Hagens Berman Investigates Johnson & Johnson for Securities Fraud after Recall of Tylenol Products
Hagens Berman is investigating claims whether pharmaceutical giant Johnson & Johnson ( JNJ ) defrauded investors by not disclosing that some of its consume... [more]
Ethicon Announces Definitive Agreement to Acquire Acclarent
SOMERVILLE, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Ethicon, Inc., a Johnson & Johnson ( JNJ ) company and a worldwide leader in surgical care, and Acclarent, Inc., a privately held medical techn... [more]
VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of O
SARATOGA, Calif., Oct. 20 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for individuals with age-related macular degeneration (A... [more]
Cordis Corporation Announces Agreement with Boston Scientific to Settle Selected Stent Litigation Ca
Cordis Corporation (“Cordis”) announced today that it has reached an agreement with Boston Scientific (“Boston”) resolving its Palmaz infringement suit relating t... [more]
NEVO™ Sirolimus-Eluting Coronary Stent Associated with Significantly Less Chest Pain at Six Months T
At six months, patients receiving the NEVO ™ Sirolimus-eluting Coronary Stent reported significantly less chest pain (also known as angina) than those... [more]
FDA Issues Complete Response Letter for Carisbamate
TITUSVILLE, N.J., Aug. 21 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an anti-epileptic drug in develo... [more]
Hagens Berman Sobol Shapiro: Parents Sue Baby Products Manufacturers After Study Shows Probable Canc
Suit calls for medical monitoring of children and others exposed to chemicals CHICAGO , March 23 /PRNewswire/ -- Some of the nation's largest child-product companies includ... [more]
Johnson & Johnson Completes Acquisition of Mentor Corporation
NEW BRUNSWICK, N.J. , Jan. 23 /PRNewswire-FirstCall/ -- Johnson & Johnson ( JNJ ) today announced the completion of its previously announced acquisition of Mentor Corporation ( MNT</... [more]
Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendere
- Johnson & Johnson Will Commence Subsequent Offering Period NEW BRUNSWICK, N.J. , Jan. 17 /PRNewswire-FirstCall/ -- Johnson & Johnson ( JNJ ) today anno... [more]
Johnson & Johnson Extends Tender Offer for Mentor Corporation
NEW BRUNSWICK, N.J. , Jan. 6 /PRNewswire-FirstCall/ -- Johnson & Johnson ( JNJ ) today announced it has extended its previously announced cash tender offer, through its wholly owned... [more]
Massachusetts Life Sciences Center Launches Tax Incentive, Early-Stage Investment Programs
The Massachusetts Life Sciences Center (MLSC), a quasi-public agency tasked with implementing the State’s $1 billion Life Sciences Initiative, will begin acceptin... [more]
Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
NEW BRUNSWICK, N.J. , Dec. 30 /PRNewswire-FirstCall/ -- Johnson & Johnson ( JNJ ) today announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals,... [more]
Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc.
NEW BRUNSWICK, N.J. , Dec. 19 /PRNewswire-FirstCall/ -- Johnson & Johnson ( JNJ ) today announced it has extended its previously announced cash tender offer, through i... [more]
Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
NEW BRUNSWICK, N.J. , Dec. 11 /PRNewswire-FirstCall/ -- Johnson & Johnson ( JNJ ) today announced that the Israeli General Director of the Antitrust Authority has approved Johnson &a... [more]
FDA Advisory Panel Unanimously Recommends Approval of NAVISTAR® THERMOCOOL® Catheter for Atrial Fibr
Biosense Webster, Inc., a Johnson & Johnson company, today reported the Circulatory System Devices Panel of the U.S. Food and Drug Administration (FDA) unanim... [more]
Jury Awards $16.5 Million in Fentanyl Death Case
CHICAGO , Nov. 17 /PRNewswire/ -- A jury in Chicago has found two Johnson & Johnson subsidiaries liable in the death of a Cicero, Ill. , woman who died whil... [more]
The Next Evolution in Training the Modern Athlete: The AchieveVision(TM) Program Helps Athletes Deve
BEIJING -- (Marketwire) -- 08/11/08 -- As millions of eyes around the globe turn to China to watch the world's top athletes go for gold at the Beijing 2008 Olympic Games, those athletes will be relying on their own vision for an extra competitive edge... [more]
India's Biocon Secures Spot in List of Top Global Biotech Majors, an Industrial Info News Alert
BANGALORE, INDIA -- (MARKET WIRE) -- 07/25/08 -- Researched by Industrial Info Resources (Sugar Land, Texas) -- A recent report released by Med Ad News ranked Biocon Limited (Bangalore, Karnataka), India's pioneer in the biotechnology space, among the... [more]
Biosense Webster Presents ''Complete Ablation Solutions'' to Electrophysiologists at Heart Rhythm 20
Biosense Webster, Inc., the worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will underscore the totality of its commitment to electrophysi... [more]
Stent Suppliers Look To Reverse Yearlong Slide
CNNMoney.com: - Mar 20, 2008 Nelson: The first were Johnson & Johnson ( NYSE:JNJ ) JNJ with the Cypher and Boston Scientific, which makes the Taxus. On Feb. 1, Medtronic (NYSE:MDT) MDT ...
Johnson & Johnson/Wharton Fellows Program in Management for Nurse ...
PR Web (press release): Johnson & Johnson/Wharton Fellows Program in Management for Nurse ... , WA - Mar 19, 2008 During the recent alumni reunion, Johnson & Johnson ( NYSE:JNJ ) announced plans to fund a full scholarship to the program for a nurse ex
The New Back Fence
Forbes: , NY - Mar 19, 2008 ... compared with BabyCenter users, who spent 14 minutes looking at 23 pages on the Johnson & Johnson ( nyse: JNJ - news - people )-owned site. ...
Roche to Amgen: We Surrender
Motley Fool: - Mar 19, 2008 The US is one of Amgen and partner Johnson & Johnson's ( NYSE: JNJ ) last major bastions of monopoly control over the erythropoiesis-stimulating-agent ...
The Best Values in China
Motley Fool: - Mar 18, 2008 There's also little doubt that consumer heavies such as Procter & Gamble, Johnson & Johnson ( NYSE: JNJ ), and Brown-Forman (NYSE: BF-B) will grow their sales ...
J&JPRD receives approvable letter from FDA for ceftobiprole for ...
Trading Markets (press release): J&JPRD receives approvable letter from FDA for ceftobiprole for ... , CA - Mar 18, 2008 ... which is using drug discovery and drug development in a variety of therapeutic areas and part of Johnson & Johnson ( NYSE:JNJ ), rep
The Panelling on Amgen's Walls
The Money Times: , India - Mar 18, 2008 The other Amgen panel hearing was related to its cancer-related anemia drugs, Aranesp and Procrit (marketed by partner Johnson and Johnson ( NYSE: JNJ ). ...
J&J unit receives FDA approvable letter
CNNMoney.com: - Mar 18, 2008 RARITAN, NJ (AP) - Johnson & Johnson ( NYSE:JNJ ) Pharmaceutical Research & Development LLC, a unit of health care company Johnson & Johnson, said Tuesday it ...
Basilea skin treatment Ceftobiprole receives approvable letter ...
CNNMoney.com: Basilea skin treatment Ceftobiprole receives approvable letter ... - Mar 18, 2008 'We are closely working together with our development partner Johnson & Johnson ( NYSE:JNJ ) Pharmaceutical Research and Development LLC to quickly a
The FDA's Call for Cash
Motley Fool: - Mar 3, 2008 ... signs of workload strain when it canceled two advisory panels for antibiotic drugs from Theravance (Nasdaq: THRX) and Johnson & Johnson ( NYSE: JNJ ). ...
FDA Floors Eli Lilly
Motley Fool: - Feb 29, 2008 Johnson & Johnson's ( NYSE: JNJ ) and Alkermes' (Nasdaq: ALKS) Risperdal Consta, which had sales of $1.1 billion last year, is the only long-acting atypical ...
This Is the Year for These Stocks
Motley Fool: What do Johnson & Johnson ( NYSE: JNJ ), EMC (NYSE: EMC), Yahoo! (Nasdaq: YHOO), Comcast (Nasdaq: CMCSA), and Disney (NYSE: DIS) have in common? ...
Before the bell 5-7-07: SNE, MOT, AAPL, DELL, JNJ ...
Blogging Stocks: - 5 hours ago CoStar drug-coated heart stents made by Conor Medsystems, which was recently acquired by Johnson & Johnson Inc. ( NYSE: JNJ ), failed in a clinical trial ...
J&J Stops Stent Study, Discontinues Sales
International Business Times: Johnson & Johnson ( NYSE: JNJ ) wholly owned firm Conor Medsystems LLCsaid, said on Monday that it will end clinical trials of its CoStar drug coated stent ...
Go Green With Buffett, Lynch and O'Shaughnessy
Forbes: PepsiCo, Johnson & Johnson ( nyse: JNJ - news - people ) and Cisco (nasdaq: CSCO - news - people )--within the past couple months. ...
Taking It to the Affymax
Motley Fool: ... to use Hematide to compete against current treatments, including Aransep, Amgen's (Nasdaq: AMGN) Epogen, and Johnson & Johnson's ( NYSE: JNJ ) Procrit. ...
Johnson & Johnson lifted by Avon's results
Blogging Stocks: - 15 hours ago Johnson & Johnson ( NYSE: JNJ ) opened at $64.53. So far today the stock has hit a low of $64.26 and a high of $64.94. As of 11:55, JNJ is trading at 64.75, ...
Kreos Capital to invest $360m in Israeli tech cos
Globes: , Israel - 5 hours ago Kreos has provided venture loans to Atrica Inc., ColBar (sold to Johnson & Johnson ( NYSE:JNJ ) a year ago), PowerPaper Ltd., and other Israeli companies. ...
Diggin' For Dividends
Forbes: , NY - 1 hour ago Example: Health care behemoth Johnson & Johnson ( nyse: JNJ - news - people ), which has increased its dividend in each of the last 44 years. ...
Red and White Results at Amgen
Motley Fool: - 6 hours ago The market is even larger, as Johnson & Johnson ( NYSE: JNJ ) sells Procrit, a near-identical compound to Epogen. The next best-selling drug, Enbrel, ...
Earnings-eluting Time at Boston Scientific: Fool by Numbers
Motley Fool: - 9 hours ago Abbott Laboratories (NYSE: ABT) and Johnson & Johnson ( NYSE: JNJ ) also have sizeable medical device businesses; they carry three- and four-star ratings, ...
Tissue Engineering: Making Blind Rats See
Forbes: , NY - 9 hours ago ... Baxter International (nyse: BAX - news - people ), Sanofi-Aventis (nyse: SNY - news - people ) and Johnson & Johnson ( nyse: JNJ - news - people ). ...
Another Rubber Tree Plant
Fast Company: - 11 hours ago Martin is a career rubber guy, first as a scientist at Johnson & Johnson ( NYSE:JNJ ), then as a sales exec for London Rubber Co. and Safeskin Corp. ...
THE Aesthetic Show Features World-Class Aesthetic Experts
PR Newswire (press release): Other corporate pioneers sponsoring THE Aesthetic Show include Mentor (NYSE: MNT), Medicis (NYSE: MRX), Johnson & Johnson ( NYSE: JNJ ), Cutera (Nasdaq: CUTR) ...
The Secrets of 9-Figure Fortunes
Motley Fool: - 6 hours ago A look at their portfolios revealed almost nothing but blue chips such as Johnson & Johnson ( NYSE: JNJ ) and General Electric (NYSE: GE). ...
Forbes: , NY - 15 hours ago ... and they respect that,” says Debra Sandler, worldwide president of McNeil Nutritionals, a division of Johnson & Johnson ( nyse: JNJ - news - people ). ...
Many Ways to Feel Good About Wyeth
Motley Fool: - 20 hours ago In the past two weeks, Eli Lilly (NYSE: LLY), Johnson & Johnson ( NYSE: JNJ ), and Schering-Plough (NYSE: SGP) have reported double-digit sales growth for ...
Zacks Analyst Blog Highlights: Abbott Labs, Boston Scientific ...
Business Wire (press release): Stocks recently featured in the blog include: Abbott Laboratories (NYSE: ABT), Boston Scientific (NYSE: BSX), Johnson & Johnson ( NYSE: JNJ ), Motorola (NYSE: ...
Vertex's Billion Dollar Drug?
Motley Fool: Over the weekend, Vertex Pharmaceuticals (Nasdaq: VRTX) and partner Johnson & Johnson ( NYSE: JNJ ) announced exciting clinical trial results for hepatitis C ...
Eisai Says Sayonara
Motley Fool: Eisai, Pfizer, and Forest Labs, along with Johnson & Johnson ( NYSE: JNJ ) and Novartis (NYSE: NVS) (among others), have said they will challenge the ruling. ...
|Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign Up||Copyright © 2014
|Never invest based soley on information from this website or our e-mail and IM alerts|